Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230060 · ClinicalTrials.gov registry record · Phase 3
One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT01230060 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 122 participants.
The verdict
NCT01230060, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the enVista® One-Piece Hydrophobic Acrylic intraocular lens (IOL), following primary implantation for the visual correction of aphakia in adults 18 years of age or older in whom the cataractous lens has been removed by an extracapsular cataract extraction method (eg, small incision phacoemulsification).
Interventions
- DEVICE enVista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01230060
The ClinicalTrials.gov registry entry for NCT01230060 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which enVista is the first listed.
NCT01230060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01230060 about?
NCT01230060 is a clinical study titled "One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction". The objective of this study is to evaluate the safety and effectiveness of the enVista® One-Piece Hydrophobic Acrylic intraocular lens (IOL), following primary implantation for the visual correction of aphakia in adults 18 years of age or older in whom the cataractous lens has been removed by an ext...
What is the current status of trial NCT01230060?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2010-10. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01230060?
The interventions under investigation include: enVista (DEVICE).
Who is sponsoring clinical trial NCT01230060?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.